Page 90 - ebook

[B. Cell Biology/Stem Cell] B-45

Targeted Cancer Stem Cell Therapy via Lysophosphatidic Acid

Pathway Inhibition in Ovarian Cancer Stem Cells

Min Joo Shin¹, Seo Yul Lee¹, Jun Se Kim¹, Seong Min Choi¹, Jae Ho Kim¹*

¹Physiology, School of medicine, Pusan national university, Yangsan 50612, Korea

Ovarian cancer shows high mortality due to resistance to chemotherapy and relapse. Cancer stem cells (CSCs) are
a subpopulation of cancers characterized by self-renewal ability, tumorigenesis and drug resistance. In previous

studies, have shown that autotaxin and lysophosphatidic acid (LPA) play an important role in CSCs characterization
such as migration, sphere forming ability and drug resistance. In this study, we found a drug that could target CSCs

by inhibiting the LPA pathway. When the LPA inhibitor was treated with A2780-SP, sphere-forming ability was
reduced compared to the treatment with KI16425 and Paclitaxel. When ovarian cancer cells and CSCs were treated

with paclitaxel showed high survival rate in CSCs. However, when LPA inhibitor was treated with ovarian cancer cells
and CSCs, survival rate was much lower in CSCs than in cancer cells. Furthermore, LPA inhibitor treatment at different

concentrations was confirmed that a concentration-dependent manner the expression is reduced ABC transporter.
When the cell death was confirmed by FACS analysis, it was confirmed that the cells were killed more by the LPA

inhibitor treatment as in the previous results. These results suggest that the LPA inhibitor may be an effective drug
for the treatment of ovarian cancer stem cells.